Sol-Gel Technologies, Ltd.

15 clinical trials · Sponsor

Record	Firm	Date
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome (NCT06050122)	Sol-Gel Technologies, Ltd.	2024-03-17
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties (NCT05675501)	Sol-Gel Technologies, Ltd.	2020-06-10
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) (NCT04308395)	Sol-Gel Technologies, Ltd.	2020-06-03
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC (NCT04155190)	Sol-Gel Technologies, Ltd.	2019-12-20
MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 (NCT04059523)	Sol-Gel Technologies, Ltd.	2019-06-27
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) (NCT03703310)	Sol-Gel Technologies, Ltd.	2019-02-19
Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream (NCT03727074)	Sol-Gel Technologies, Ltd.	2018-12-21
A Study of S6G5T-3 in the Treatment of Acne Vulgaris (NCT03761784)	Sol-Gel Technologies, Ltd.	2018-12-21
A Study of S6G5T3 in the Treatment of Acne Vulgaris (NCT03761810)	Sol-Gel Technologies, Ltd.	2018-12-14
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea (NCT03564119)	Sol-Gel Technologies, Ltd.	2018-06-21
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea (NCT03448939)	Sol-Gel Technologies, Ltd.	2018-06-18

Track Sol-Gel Technologies, Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.